Xconomy

SEPTEMBER 30, 2016

Who will be first to market with a new type of cancer treatment known as CAR-T? Who will break free of the pack of companies developing drugs meant to prevent migraines? —Sarepta inked a research pact with Catabasis Pharmaceuticals (NASDAQ: CATB ) to develop a combination therapy for Duchenne.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

AUGUST 26, 2016

Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. It will retain the PixarBio name and aims to start trading on the over-the-counter market during the second week of September. Morgan party.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

JULY 22, 2016

Xconomy spoke with CEO Tom Hughes about the decision, which is terrible news for patients with the rare disease Prader-Willi Syndrome; Zafgen had hoped to win FDA approval of beloranib in Prader-Willi, which would have made it the first marketed drug for the disease since human growth hormone over a decade ago.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

Instead, Holmes promoted a new system, MiniLab , in development. As a result, Biogen will buy the rights to nusinersen and prepare to ask regulators for marketing approval. Holmes claimed it would be able to produce multiple test results from a single blood sample without shipping blood to a lab. SMA has no approved treatments.

News 40

News Thousand Oaks Pricing Report 40

Xconomy

JUNE 10, 2016

—More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga. —On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67